The proposed experiments are designed to generate monoclonal antibodies which will allow us to identify aspects of glial neoplasms which are pertinent to predicting clinical course, and which may aid in planning therapy. The antibodies may also prove useful as tools with which to understand malignant transformation, and as therapeutic reagents. We have in previous work generated a large panel of mouse monoclonal antibodies which bind to normal rodent astrocytes. We now propose to determine whether any of these antibodies to normal cell components bind selectively or disproportionately to epitopes present in human neoplasms. The panel of antibodies will be screened to detect antibodies which bind to cultured normal human astrocytes, and to cultured neoplastic astrocytes. The panel will also be screened for antibodies which bind to tumor cells in biopsies taken at the time of neurosurgery. It has been established by others that antibodies to normal cell constituents are powerful tools which allow one to recognize sub-types in tumors, and to correlate the tumor appearance with clinical behavior. Using techniques which have succeeded in generating antibodies in rodent tissue, we now plan to generate monoclonal antibodies which bind to epitopes expressed selectively by human glial neoplasms. We will immunize mice with plasmalemmal fractions from cultured normal human astrocytes, and the kill the responding lymphocytes with cyclophosphamide. Next, the same animals will be immunized with plasmalemmal fractions from neoplastic cells, which should elicit an immune response directed against epitopes expressed in neoplastic but not normal astrocytes. Such tumor-specific antibodies should prove an even more powerful approach to defining sub-types of human neoplasms, and correlating immunophenotype with clinical behavior. Further, such antibodies can be used as immunotherapeutic reagents. Finally, selective monoclonal antibodies may serve as starting points for cloning the genes whose expression is regulated during neoplastic transformation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA060171-01
Application #
3774181
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Chen, W S; Kung, H J; Yang, W K et al. (1999) Comparative tyrosine-kinase profiles in colorectal cancers: enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. Int J Cancer 83:579-84
Qiu, Y; Robinson, D; Pretlow, T G et al. (1998) Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 95:3644-9
McKeon, R J; Silver, J; Large, T H (1997) Expression of full-length trkB receptors by reactive astrocytes after chronic CNS injury. Exp Neurol 148:558-67
Zhang, D; Jacobberger, J W (1996) TGF-beta 1 perturbation of the fibroblast cell cycle during exponential growth: switching between negative and positive regulation. Cell Prolif 29:289-307
Garner, A S; Menegay, H J; Boeshore, K L et al. (1996) Expression of TrkB receptor isoforms in the developing avian visual system. J Neurosci 16:1740-52
Ling, L; Templeton, D; Kung, H J (1996) Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J Biol Chem 271:18355-62
Ling, L; Kung, H J (1995) Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 15:6582-92
Garner, A S; Large, T H (1994) Isoforms of the avian TrkC receptor: a novel kinase insertion dissociates transformation and process outgrowth from survival. Neuron 13:457-72
Shu, H K; Chang, C M; Ravi, L et al. (1994) Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain. Mol Cell Biol 14:6868-78